Navigation Links
CV Therapeutics Reports 2008 First Quarter Financial Results
Date:4/25/2008

he Investor Information section. Alternatively, domestic callers may participate in the conference call by dialing (866) 524-6241, and international callers may participate in the conference call by dialing (706) 679-3061. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Friday, May 2, 2008. Domestic callers can access the replay by dialing (800) 642-1687, and international callers can access the replay by dialing (706) 645-9291; the PIN access number is 43615588.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved products include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. CV Therapeutics also has other clinical and preclinical drug development candidates and programs.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment ag
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
(Date:1/14/2014)... Texas , Jan. 14, 2014 The ... and research medicinal plants and therapeutic derivatives thereof ... health professionals, and researchers about the challenges of ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), ... solutions for patients, physicians, the biopharmaceutical industry, regulators, ... the signing of a three-year Research Collaboration Agreement ... (FDA). This initiative is designed to generate ...
(Date:1/14/2014)... 14, 2014 Independent publisher Bitingduck Press, ... Montreal, Canada, has big ideas for 2014 in production ... goals are to produce high-quality, low-cost, DRM-free ebooks and ... businesses. , The first major development will be ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... Caffeine Test Strips, to Know for Sure, Studies show that ... ... levels of caffeine, MONROVIA, Calif., Nov. 12 Ever wonder whether ... for sure,with new D+CAF, the first ever do-it-yourself caffeine test strip from,Silver ...
... MaxCyte, Inc.,the pioneer in scalable, high performance ... a live discussion with industry experts on the,challenges ... discussion is open to the industry and will ... 2:00-3:00EST., One of the respected industry experts ...
... Implementation Issues and Recommendations, BETHLEHEM, Pa., ... of Clinical Value Marketing, Infusion Systems Division ... Services for B. Braun Medical,Inc. (B. Braun), ... and services,recently represented B. Braun at the ...
Cached Biology Technology:Is Your Decaf Really Decaf? 2MaxCyte Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery 2B. Braun Directors Participate at First ISMP National Smart Pump Safety Summit 2B. Braun Directors Participate at First ISMP National Smart Pump Safety Summit 3
(Date:7/9/2014)... bladders of healthy women differ from bacteria in ... to researchers from Loyola University Chicago Stritch School ... 9, 2014, in the American Society for Microbiology,s ... communities may play a role in female urinary ... common, yet poorly understood, condition with symptoms similar ...
(Date:7/9/2014)... Centre (CNIO) have discovered that NANOG, an essential gene ... stratified epitheliathose that form part of the epidermis of ... adult organisms. According to the conclusions of the study, ... factor could also play a role in the formation ... and skin. , The pluripotency factor NANOG is active ...
(Date:7/9/2014)... studying critically ill children with traumatic injuries have ... are likely to develop a hospital-acquired infection. The ... and published online in June in the journal ... efforts that could lead to the clinical implementation ... prevent or reverse immune system damage following critical ...
Breaking Biology News(10 mins):CNIO scientists discover that pluripotency factor NANOG is also active in adult organisms 2Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
... Dana-Farber Cancer Institute (Dana-Farber), Burnham Institute for Medical ... and Prevention (CDC) have reported the identification of ... range of influenza A viruses, including avian influenza ... some seasonal influenza viruses. These antibodies have the ...
... International, Inc. (OTC Bulletin Board: BKYI), a leader in ... today that it will participate in Imperial Capital,s Homeland ... of March. Additional details regarding BIO-key,s participation at ... , Imperial Capital,s ...
... Permanently Disposes Magnetically Recorded Data to Help QSGI,s ... Calif., Feb. 18 Fujitsu Computer Products of ... products including hard disk drives, peripherals and biometric ... using the Fujitsu Mag EraSURE degaussing ...
Cached Biology News:Scientists identify human monoclonal antibodies effective against bird and seasonal flu viruses 2Scientists identify human monoclonal antibodies effective against bird and seasonal flu viruses 3BIO-key(R) Announces Conference Schedule 2QSGI Integrates Fujitsu Mag EraSURE Data Degausser into its Suite of Information Technology Security Services 2QSGI Integrates Fujitsu Mag EraSURE Data Degausser into its Suite of Information Technology Security Services 3QSGI Integrates Fujitsu Mag EraSURE Data Degausser into its Suite of Information Technology Security Services 4QSGI Integrates Fujitsu Mag EraSURE Data Degausser into its Suite of Information Technology Security Services 5
... The dsRNA Marker consists of ten ... 200, 300, 400, 500 and 1,000 base ... size marker for determinating sizes of double-stranded ... in the dsRNA Marker is adjusted to ...
... size markers are a mixture of Strep•Tag® ... 100 kDa. The markers provide precise size ... staining with Coomassie blue. Because each of ... the markers can also be detected by ...
Mouse monoclonal antibody to ACP2 - acid phosphatase 2, lysosomal...
... V, is used for agitation and mixing applications ... and destaining of gels and blots, and Southern ... rpm) and can handle a maximum load of ... 29 x 21 cm platforms covered with nonslip ...
Biology Products: